CM
COGT icon

Crestline Management’s Cogent Biosciences COGT Stock Holding History

Crestline Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-369,763
Closed -$2.88M – 133
2024
Q4 		$2.88M Hold
369,763
– – 0.1% 220
2024
Q3 		$3.99M Buy
369,763
+43,693
+13% +$425K 0.21% 127
2024
Q2 		$2.75M Buy
326,070
+11,070
+4% +$84K 0.21% 119
2024
Q1 		$2.12M Buy
+315,000
New +$1.95M 0.19% 132

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Crestline Management's COGT Position: Q1 2025 in Review

Crestline Management sold out of Cogent Biosciences (COGT) in Q1 2025, closing a stake of 369,763 shares — an estimated $2.88M sold.

Crestline Management first reported a position in COGT in Q1 2024 and held it in 4 quarters. The position peaked at $3.99M in Q3 2024. 186 funds tracked by Wall St. Rank hold COGT as of Q1 2025.

  • Crestline Management reported no remaining Cogent Biosciences position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 369,763 Cogent Biosciences shares in Q1 2025, an estimated $2.88M.
  • Crestline Management first reported a position in Cogent Biosciences in Q1 2024 and held it in 4 quarters.
  • Crestline Management's Cogent Biosciences position peaked at $3.99M in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.